ImmunityBio, Inc. (FRA:26CA)
Germany
· Delayed Price · Currency is EUR 1.964
+0.104 (5.59%)
At close: Dec 4, 2025
ImmunityBio Revenue
ImmunityBio had revenue of $32.06M USD in the quarter ending September 30, 2025, with 425.07% growth. This brings the company's revenue in the last twelve months to $82.56M, up 1,025.95% year-over-year. In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth.
Revenue (ttm)
$82.56M
Revenue Growth
+1,025.95%
P/S Ratio
27.61
Revenue / Employee
$121.40K
Employees
680
Market Cap
1.94B EUR
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |